Drug discontinuation: Iron Sucrose Injection (IRON SUCROSE)
FDA lists 1 presentation as To Be Discontinued. Companies: Mylan Institutional, a Viatris Company.
- Published by source
- 2026-05-21
- First seen by Reality Radar
- 2026-10-22
- Last verified
- 2026-10-22
Affected
- Manufacturer
- Mylan Institutional, a Viatris Company
- Products
- Iron Sucrose Injection IRON SUCROSE
Whether your exact unit is affected depends on the model, serial number and region in the official notice.
What the official notice says
Risk: To Be Discontinued
Remedy / actions:
- A business decision has been made to discontinue of 2.5mL presentation only. Continuity of supply is forecasted across all other presentations of Iron Sucrose: 67457-639-10 Iron Sucrose 20mg/mL 10mL SDV 5PK 67457-638-10 Iron Sucrose 20mg/mL 5mL SDV 10PK 67457-638-25 Iron Sucrose 20mg/mL 5mL SDV 25PK.
Is this affecting you?
Add what you own or use and Reality Radar will tell you when official changes match it — with evidence and next steps.
Sources
- openFDA Drug Shortages Tier A · official published 2026-05-21
Evidence ledger
Every piece of evidence we store is appended to a public hash chain, so later edits are detectable. Anyone can re-verify it.
| Entry | Kind | Observed | Evidence hash | Entry hash |
|---|---|---|---|---|
| #1042 | new | 2026-10-22 | 342e4cc300e1…0768f8 | fa9cca2ce812…d75928 |
Chain head: #1076 8ad5adc30b9b…88ce20